Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Friday. JAZZ has been the subject of a number of other reports. Stifel Nicolaus upped their price target on shares of Jazz Pharmaceuticals from $225.00 to […]